Ki Y. Chung

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

Ki Y. Chung, Jinru Shia, Nancy E. Kemeny et al. · Journal of Clinical Oncology · 2005 · 1.1K citations · Full text

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav et al. · The Lancet Oncology · 2021 · 392 citations

Oncology, Gastrointestinal Oncology, Colorectal Cancer +5

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

Ki Y. Chung, Ira Gore, Lawrence Fong et al. · Journal of Clinical Oncology · 2010 · 303 citations · Full text

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

Jinru Shia, David S. Klimstra, Allan R. Li et al. · Modern Pathology · 2005 · 163 citations · Full text

Tumor Biology, Gene Amplification, Medicine +9